1. Introduction {#s0005}
===============

The global burden of neonatal and child mortality is alarmingly high in low and middle income countries (LMICs). There has been a sharp decline in mortality rates in children under five years of age between 1990 and 2013 (from 90 mortalities per 1000 down to 46 mortalities per 1000 live births between 1990 and 2013). This rate needs to further decrease, to just 30 mortalities per 1000 live births, in order to meet the Millennium Development Goals (MDGs) 2015 target ([@bb0005]).

Despite all the progress made in the last decade, it is very unlikely that the MDG targets will be met in many LMICs, where 99% of global deaths occur ([@bb0005]). In countries with a high burden of neonatal and child mortality, a variety of interventions could substantially reduce deaths and improve maternal and perinatal outcomes. Interventions and care primarily employed during different periods from antenatal to the later childhood period can facilitate reductions in neonatal and later mortality. However, a major obstacle in meeting the proposed reduction is that most neonatal and child health programs do not reach to those who need it the most. Therefore, effective interventions and care-based strategies need to be widely deployed to all and be delivered across the continuum of reproductive, maternal, neonatal and child health (RMNCH) care.

As we approach the deadline for the target of the MDGs and begin the journey towards achieving sustainable development goals (SDGs) we must focus efforts on programs and interventions shown to work. Several systematic reviews have evaluated the role of individual antenatal, natal, postnatal and child health interventions and their potential role at improving morbidity and mortality, however, there has been no overview on these interventions. Such an overview of systematic reviews of interventions to prevent neonatal and child mortality would facilitate the development of a definitive framework for preventing neonatal and child mortality in LMICs.

2. Methodology {#s0010}
==============

In this overview of reviews, we have included all published Cochrane and the most recent (most latest on the given subject) other systematic reviews of randomized, non-randomized controlled trials of interventions and observational studies aiming to prevent perinatal (stillbirths + early neonatal mortality) or neonatal or child mortality (or stillbirths where either of these were not reported). We included interventions considered for improving neonatal and child survival and provided during pre-pregnancy, antenatal, childbirth and postnatal periods to mothers or the infant or child included in a set of 61 RMNCH interventions reported as essential interventions for reproductive, maternal, newborn and child health by the World Health Organization (WHO) ([Panel 1](#t0010){ref-type="table"}) ([@bb0010]). We considered reviews that included women of reproductive age, including pregnant women at any stage of gestation, their newborns and children up to five years of age. This overview considered reviews on interventions which were compared against no placebo or treatment or control group (unless otherwise indicated).

All available recent non-Cochrane and updated or most recent Cochrane systematic reviews were identified from the Cochrane Library and PubMed using the search strategy devised for each intervention separately during Nov 2012 to Jan 2013 (Supplementary Table 1). The search terms were limited to title, abstract, or keywords. The methodology for data collection and analysis is based on the Cochrane Handbook of Systematic Reviews of Interventions ([@bb0015]). The outcomes of interest for this overview of reviews were perinatal mortality, neonatal mortality, infant mortality and under-five mortality reported as primary or secondary outcomes in included reviews.

The protocol for this overview is registered with PROSPERO 2014: CRD42014007091 (<http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007091#.U75a1RCLMiw>). Two review authors (ZSL and PM) independently assessed the inclusion of all the potential systematic reviews and extracted information using a predefined form (intervention, comparison, mortality outcome, type of studies included --- Characteristics of included reviews Supplementary Table 2). Any disagreement was resolved through discussion or, where required, we consulted a third person. We addressed two different quality assessments in this overview: the quality of evidence in the included reviews ([Table 1](#t0005){ref-type="table"}) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach ([@bb0020], [@bb0025]) and the methodological quality of the systematic reviews using the 'assessment of multiple systematic reviews' (AMSTAR) measurement tool ([@bb0030]) (Supplementary Table 3). We did not update individual reviews. Where reviews did not prepare and report mortality outcomes using GRADE-pro software ([@bb0035]), we formulated 'summary of findings' tables. The following criteria were taken into account to grade the evidence: study limitations (risk of bias for the outcome of interest), consistency of effect, imprecision, indirectness, and publication bias. We summarised the main results of the included reviews into following categories.•What works?Effective interventions: indicating that the review found high quality evidence with the effect likely to be similar to research findings.•What might work?Promising interventions (more evidence needed): indicating that the review found moderate quality evidence with the effect expected to be similar to research findings, but with a possibility that it will be substantially different in the future.•Insufficient evidence to make judgementIneffective or probably ineffective interventions: indicating that the review found low or very low quality evidence of effectiveness or lack of effectiveness for an intervention.For low quality of evidence, it is likely that the effect will be substantially different from research findings, but that these will indicate what might be expected.For very low quality of evidence, the anticipated effect is very uncertain and the research does not provide a reliable indication of what might be expected.

3. Funders and Their Role {#s0015}
=========================

This review was part of doctoral thesis which was funded by University of Adelaide, Australia. The funders had no role in the study design, study conduct, data analysis, data interpretation, or writing of the report. All authors take responsibility for the integrity and the accuracy of the data. The corresponding author had final responsibility to submit the report for publication.

4. Results {#s0020}
==========

The overview included 61 reproductive (n = 3), maternal (pregnancy: n = 15; childbirth: n = 11; postpartum: n = 4), newborn (n = 12) and child (n = 16) health interventions to assess their impact on neonatal and child survival ([Panel 1](#t0010){ref-type="table"}). A total of 148 systematic reviews were identified for these 61 RMNCH interventions, of which 92 were Cochrane reviews, 55 were non-Cochrane reviews and one was a WHO guideline on management of unintended pregnancy. Of these 148 reviews, only 57 reviews reported mortality outcomes ([Panel 2](#t0015){ref-type="table"}).

Using the GRADE approach, we identified six interventions to be clearly effective in reducing neonatal, infant or child mortality (corticosteroids for preventing neonatal respiratory distress syndrome in preterm infants; early initiation of breastfeeding; hygienic cord care; kangaroo care for preterm infants; provision and promotion of use of insecticide treated bed nets (ITNs) for children; and vitamin A supplementation for infants from six months of age).

We identified 11 promising interventions for reducing neonatal, infant, child or perinatal mortality (antenatal care; tetanus immunization in pregnancy; prophylactic antimalarial during pregnancy; induction of labour for prolonged pregnancy; case management of neonatal sepsis, meningitis and pneumonia; prophylactic and therapeutic use of surfactant; continuous positive airway pressure; case management of childhood malaria; case management of childhood pneumonia; vitamin A as part of treatment for measles associated pneumonia for children above 6 months; and home visits across the continuum of care) and a further four interventions were rated as promising for reducing stillbirths (prophylactic antimalarial during pregnancy; provision and promotion of ITNs during pregnancy; induction of labour for prolonged pregnancy; and home visits across the continuum of care). Eighteen interventions showed insufficient evidence of benefit in one or more of the mortality categories ([Table 1](#t0005){ref-type="table"}).

4.1. Effective Interventions {#s0025}
----------------------------

### 4.1.1. Corticosteroids for Preventing Neonatal Respiratory Distress Syndrome (RDS) {#s0030}

This overview identified three reviews ([@bb0040], [@bb0045], [@bb0050]), of which two ([@bb0040], [@bb0045]) reviewed the impact of antenatal corticosteroids on the mother before anticipated preterm birth (with additional analysis for women in LMICs) ([@bb0040]). Brownfoot and colleagues ([@bb0050]) assessed different corticosteroid regimens. Two reviews reported the impact of corticosteroids on neonatal mortality ([@bb0040], [@bb0045]). Roberts and Dalziel pooled 18 trials on 3956 women at risk of preterm birth and found a 31% (Risk Ratio (RR) 0.69; 95% Confidence Interval (CI): 0.58, 0.81) reduction in neonatal mortality (high GRADE rating) in women who were given antenatal corticosteroids compared to women who were not given any corticosteroids or given placebo ([@bb0045]). Mwansa-Kambafwile and colleagues ([@bb0040]) reported a 31% (RR 0.69; 95% CI: 0.58, 0.81) reduction (high GRADE rating) in preterm-specific mortality on pooling 18 trials on 3956 women mostly from high-income countries and 53% (RR 0.47; 95% CI: 0.35, 0.64) reduction in preterm-specific mortality on pooling a subset of four trials on 672 women from middle-income countries who were given antenatal corticosteroids.

### 4.1.2. Early Initiation of Breastfeeding {#s0035}

The overview identified six reviews ([@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]) that reported the impact of different interventions on improving early initiation of breastfeeding. Lewin and colleagues ([@bb0060]) and Lassi and colleagues ([@bb0065]) assessed the impact of interventions delivered through lay health workers and in the form of packages, respectively, on improving breastfeeding rates. These reviews reported reductions in mortality; however, reduction in deaths may have been achieved by other parts of the intervention package and therefore the reduction does not necessarily reflect the impact of a breastfeeding intervention alone. Dyson and colleagues ([@bb0055]), Imdad and colleagues ([@bb0070]), and Lumbiganon and colleagues ([@bb0080]) did not report outcomes on mortality. The review by Debes and colleagues ([@bb0075]) identified 18 studies, of which three prospective cohort studies (including 44,249 newborns) with moderate GRADE quality showed neonatal mortality was reduced by 44% (RR 0.56; 95% CI: 0.40, 0.79) with early initiation of breastfeeding (within less than 24 h of birth).

### 4.1.3. Hygienic Cord Care {#s0040}

The overview identified two reviews, of which Zupan and colleagues assessed topical cord care ([@bb0085]) and the other two by Imdad and colleagues assessed chlorhexidine application alone and other application for cord care and included almost similar studies ([@bb0090], [@bb0095]). The latter two reported neonatal mortality ([@bb0090], [@bb0095]). Pooled analysis of three studies (n = 54,561) found a moderate GRADE quality and significant 23% (RR 0.77; 955 CI: 0.63, 0.94) reduction in neonatal mortality with the application of chlorhexidine when compared with no application to the umbilical cord (dry cord care) ([@bb0090], [@bb0095]). However the Cochrane review by Imdad and colleagues also compared washing the cord with dry care, reporting no difference in all-cause mortality (RR 1.00; 95% CI: 0.76, 1.32, moderate GRADE quality) ([@bb0095]).

### 4.1.4. Kangaroo Mother Care for Preterm Infants {#s0045}

The overview identified two reviews ([@bb0100], [@bb0105]) that assessed the impact of kangaroo mother care (KMC) on preterm and low birth weight infants (\< 2000 g) and reported mortality outcome. Pooled analysis of 11 studies from 2167 infants reported a significant 33% reduction in mortality (moderate GRADE quality) at the latest follow up (RR 0.67; 95% CI: 0.48, 0.95) ([@bb0105]). The meta-analysis of three randomized controlled trials (RCTs) (n = 1075) --- a subset of those pooled in the latest Cochrane review ([@bb0105]) --- that provided KMC to infants in the first week of life showed a significant 51% reduction in neonatal mortality (RR 0.49; 95% CI: 0.29, 0.82 --- high GRADE quality) when compared to standard care ([@bb0100]). This review also pooled three observational studies and found a similar beneficial impact on neonatal mortality (RR 0.68; 95% CI: 0.58, 0.79) ([@bb0100]).

### 4.1.5. Provision and Promotion of use of ITNs for Children {#s0050}

The overview identified one review that pooled five studies on 149,221 children and compared ITNs with control and found a significant 18% reduction in child mortality (RR 0.82; 95% CI: 0.76, 0.89 --- moderate GRADE quality) ([@bb0110]).

### 4.1.6. Vitamin A Supplementation From 6 Completed Months of age {#s0055}

The overview identified three reviews from the same review authors who assessed the impact of vitamin A supplementation from six months of age, and reported neonatal mortality ([@bb0115], [@bb0120], [@bb0125]). In the latest of these, pooling of 17 trials including 194,795 children found that vitamin A supplementation is effective in reducing all-cause mortality by 24% (RR 0.76; 95% CI: 0.69, 0.83) when compared with no treatment or placebo ([@bb0115]). The quality was high on GRADE analysis.

4.2. Promising Interventions {#s0060}
----------------------------

### 4.2.1. Antenatal Care {#s0065}

The overview identified two reviews ([@bb0130], [@bb0135]) assessing the impact of fewer than usual antenatal care visits. This review of five trials including 108,002 pregnant women identified that reduced number of antenatal care visits (ranged 4--9) was associated with 14% higher risk of perinatal mortality (RR 1.14; 95% CI: 1.00, 1.31) when compared with standard antenatal care visits (ranged 12--14 +) ([@bb0130]), indicating that fewer antenatal visits than the standard number may be harmful. Another review, comparing group with standard antenatal care did not detect significant differences in perinatal mortality (RR 0.59; 95% CI: 0.22, 1.52; 2 trials, n = 1315) ([@bb0140]).

### 4.2.2. Tetanus Immunization in Pregnancy {#s0070}

The overview identified two reviews on tetanus toxoid (TT) vaccination versus placebo: Demicheli and colleagues ([@bb0145]) compared TT vaccination with influenza and cholera vaccination, whereas Blencowe and colleagues ([@bb0150]) compared TT immunization with no immunization. The comparison of TT with influenza and cholera was judged as low quality and therefore included in "insufficient evidence interventions" section. The meta-analyses from Blencowe and colleagues ([@bb0150]) displayed a significant impact of TT immunization on reducing neonatal mortality when compared with no immunization (RR 0.06; 95% CI: 0.02, 0.20; two studies, n = 2146). This review pooled two studies, of which one was an experimental trial and the other was an observational study.

### 4.2.3. Prophylactic Antimalarials During Pregnancy {#s0075}

The overview identified four reviews on prophylactic antimalarial and intermittent preventive treatment (IPT) in pregnancy ([@bb0155], [@bb0160]). Two reviews reported outcomes on neonatal mortality and perinatal mortality ([@bb0155], [@bb0160]), whereas one reported stillbirths ([@bb0160]).

#### 4.2.3.1. Neonatal Mortality {#s0080}

Radeva-Petrova and colleagues assessed antimalarial drug prophylaxis (e.g. chloroquine given weekly) or IPT (typically sulfadoxine-pyrimethamine given two to three times during pregnancy) with no regular or routine antimalarial or comparator IPT and found a non-significant 7% reduction in neonatal and infant mortality (RR 0.93; 95% CI: 0.76, 1.14 --- low GRADE quality) on pooling nine trials including 10,486 women in their first or second pregnancy ([@bb0160]). The review by Eisele and colleagues compared IPT with control and found a non-significant 17% reduction in neonatal mortality (RR 0.83; 95% CI: 0.52, 1.20 --- moderate GRADE quality) ([@bb0155]).

#### 4.2.3.2. Perinatal Mortality {#s0085}

Radeva-Petrova and colleagues pooled six trials on 6836 women in their first or second pregnancy and found a non-significant 1% reduction in perinatal mortality (RR 0.99; 95% CI: 0.81, 1.22 --- low GRADE quality) ([@bb0160]). Eisele and colleagues found a non-significant 17% reduction in perinatal mortality (RR 0.83; 95% CI: 0.52, 1.20 --- moderate GRADE quality) ([@bb0155]).

#### 4.2.3.3. Stillbirths {#s0090}

Radeva-Petrova and colleagues pooled seven trials on 9833 women in their first or second pregnancy and reported a non-significant increase in stillbirths (RR 1.01; 95% CI: 0.79, 1.28 --- low GRADE quality) ([@bb0160]).

### 4.2.4. Provision and Promotion of ITNs During Pregnancy {#s0095}

The overview identified two reviews by Gamble and colleagues ([@bb0170], [@bb0165]) that studied the effect of ITN on pregnant women and reported moderate GRADE quality foetal loss. Pooled analysis of five trials reported a significant 32% reduction in foetal loss (miscarriage or stillbirths) (RR 0.68; 95% CI: 0.48, 0.98) ([@bb0170]). A subset of those trials pooled in the Cochrane review reported a significant 32% reduction in foetal loss (miscarriage or stillbirths) (RR 0.68; 95% CI: 0.48, 0.89; three studies, n = 4557) ([@bb0165]).

### 4.2.5. Induction of Labour for Prolonged Pregnancy {#s0100}

The overview identified two reviews that evaluated the benefits and harms of a policy of labour induction at term or post-term compared with awaiting spontaneous labour or later induction of labour ([@bb0175], [@bb0180]). Both of the reviews included almost the same set of studies and reported outcomes on perinatal mortality and stillbirths ([@bb0175], [@bb0180]), while only Gulmezoglu and colleagues reported neonatal mortality ([@bb0175]).

#### 4.2.5.1. Neonatal Mortality {#s0105}

The meta-analysis by Gulmezoglu and colleagues found a moderate GRADE quality non-significant 63% (RR 0.37; 95% CI: 0.10, 1.38; 17 studies, n.7407) reduction in neonatal deaths within seven days when compared with labour induction at term or post-term with awaiting spontaneous labour or later induction of labour ([@bb0175]).

#### 4.2.5.2. Perinatal Mortality {#s0110}

The meta-analysis of 17 studies on 7407 women by Gulmezoglu and colleagues found a significant 69% (RR 0.31; 95% CI: 0.12, 0.81 --- moderate GRADE quality) ([@bb0175]) and meta-analysis of 14 studies on 6597 women by Hussain and colleagues found a significant 69% (RR 0.31; 95% CI: 0.11, 0.88 --- moderate GRADE) ([@bb0180]) reduction in perinatal mortality with induced labour at term or post-term.

#### 4.2.5.3. Stillbirths {#s0115}

The meta-analysis of 17 studies on 7407 women by Gulmezoglu and colleagues found a non-significant 70% (RR 0.30; 95% CI: 0.08, 1.08 --- moderate GRADE quality) ([@bb0175]) and meta-analysis of 14 studies on 6597 women by Hussain and colleagues found a 71% (RR 0.29; 95% CI: 0.06, 1.38 --- moderate GRADE quality) ([@bb0180]) reduction in stillbirths.

### 4.2.6. Case Management of Neonatal Sepsis, Meningitis and Pneumonia {#s0120}

The overview identified four reviews that assessed the impact of case management of diagnosed sepsis, meningitis and pneumonia among neonates ([@bb0185], [@bb0190], [@bb0195], [@bb0200]). Among these, two reviews reported an impact on mortality which was moderate on GRADE quality ([@bb0195], [@bb0200]). Case management of neonatal infectious diseases reported 27% (RR 0.73; 95% CI: 0.65, 0.82) ([@bb0200]) and 25% (RR 0.75, 95% CI: 0.64, 0.89; 4 studies) ([@bb0195]) reduction in all-cause mortality. Similarly, the reviews also reported reduction in pneumonia specific mortality by 42% (RR 0.58; 95% CI: 0.43, 0.78) ([@bb0200]) and (RR 0.58; 95% CI: 0.41, 0.82; 3 studies) ([@bb0195]).

### 4.2.7. Prophylactic and Therapeutic use of Surfactant {#s0125}

The overview identified three reviews on the impact of prophylactic and therapeutic use of surfactant and reported moderate quality GRADE outcomes on neonatal mortality ([@bb0205], [@bb0210], [@bb0215]). Soll pooled six studies on 2352 newborns that compared synthetic surfactant with placebo and found a significant 27% reduction in neonatal mortality (RR 0.73; 95% CI: 0.61, 0.88) ([@bb0210]). Soll and Ozek assessed the impact of multiple doses of surfactant with single dose from three trials on 1220 newborns with severe RDS and found a significant 41% reduction in neonatal mortality (RR 0.59; 95% CI: 0.44, 0.78) ([@bb0205]). Bahadue and Soll compared early versus delayed selective surfactant treatment for RDS from six studies (n = 3577) and found a significant 16% reduction in neonatal mortality (RR 0.84; 95% C: 0.74, 0.95) ([@bb0215]).

### 4.2.8. Continuous Positive Airway Pressure (CPAP) {#s0130}

The overview identified three reviews ([@bb0220], [@bb0225], [@bb0230], [@bb0235]), of which two reported mortality as an outcome ([@bb0220], [@bb0230], [@bb0235]). Greenough 2008 compared high frequency positive pressure ventilation (HFPPV) with conventional ventilation (CMV) and reported a non-significant 20% reduction in neonatal mortality (RR 0.80; 95% CI: 0.62, 1.03; three studies, n = 585 --- moderate GRADE) ([@bb0220]). Ho and colleagues compared continuous distending pressure (CDP) with standard care and found a significant 48% reduction in neonatal mortality (RR 0.52; 95% CI: 0.32, 0.87; six studies, n = 355 --- moderate GRADE) ([@bb0230]). Subramaniam and colleagues, compared prophylactic CPAP with control and reported an increase in neonatak deaths with prophylactic use (RR 1.29; 95% CI: 0.45, 3.67 --- low GRADE) ([@bb0235]).

### 4.2.9. Case Management of Childhood Malaria {#s0135}

The overview identified four reviews ([@bb0155], [@bb0240], [@bb0245]), of which Thwing and colleagues reported a reduction in malaria mortality in children 1 to 23 months (RR 0.01; 95% CI: 0.00, 0.06) and in children 24 to 59 months of age (RR 0.03; 95% CI: 0.01, 0.14 --- moderate GRADE quality) ([@bb0245]). Meremikwu and colleagues compared IPT versus placebo or no IPT and reported a non-significant reduction in child mortality (RR 0.66; 95% CI: 0.31, 1.39; six studies, n = 9533 --- moderate GRADE quality) ([@bb0240]).

### 4.2.10. Case Management of Childhood Pneumonia {#s0140}

The overview identified four reviews ([@bb0250], [@bb0255], [@bb0260], [@bb0265]), of which two reviews reported mortality as an outcome. Both of these reviews reported a significant reduction in acute lower respiratory tract infections (ALRI) specific mortality (RR 0.65; 95% CI: 0.52, 0.82; nine studies) ([@bb0250]); (RR 0.65; 95% CI: 0.52, 0.82) ([@bb0265]) and all-cause mortality (RR 0.79; 95% CI: 0.70, 0.82; nine studies);[@bb0250] (RR 0.68; 95% CI: 0.53, 0.86) ([@bb0265]) with case management of pneumonia when compared to standard or no care. The evidence was moderate quality on GRADE analysis.

### 4.2.11. Vitamin A as Part of Treatment for Measles-Associated Pneumonia for Children Above 6 Months {#s0145}

The overview identified two reviews ([@bb0270], [@bb0275]), of which one reported mortality ([@bb0270]). This review pooled eight studies on 135,609 children and compared vitamin A supplementation with none for measles associated pneumonia and reported a significant 30% reduction in child mortality (RR 0.70; 95 CI: 0.56, 0.87 --- moderate GRADE quality) ([@bb0270]).

### 4.2.12. Home Visits Across the Continuum of Care women\'s Groups {#s0150}

The overview identified four reviews ([@bb0065], [@bb0280], [@bb0285], [@bb0290]). Only two reviews ([@bb0065], [@bb0290]) assessed home visitation as part of delivery strategy. Both of these reviews reported outcome on neonatal mortality ([@bb0065], [@bb0290]), whereas only one reported outcomes on perinatal mortality and stillbirths ([@bb0065]).

#### 4.2.12.1. Neonatal Mortality {#s0155}

The review by Lassi and colleagues reported a 22% reduction in neonatal mortality (RR 0.78; 95% CI: 0.67, 0.92 --- moderate GRADE quality) on pooling five studies on 56,878 participants ([@bb0065]). On the other hand, Gogia 2010 pooled five studies and reported a 38% reduction in neonatal mortality (RR 0.62; 95% CI: 0.44, 0.87 --- moderate GRADE quality) ([@bb0290]).

#### 4.2.12.2. Perinatal Mortality {#s0160}

The review by Lassi and colleagues pooled three studies on 45,835 participants and reported a 28% reduction in perinatal mortality (RR 0.72; 95% CI: 0.61, 0.85 --- moderate GRADE quality) ([@bb0065]).

#### 4.2.12.3. Stillbirths {#s0165}

The review by Lassi and colleagues pooled three studies on 45,835 participants and reported a 27% reduction in stillbirths (RR 0.73; 95% CI: 0.67, 0.81 --- moderate GRADE quality) ([@bb0065]).

4.3. Ineffective or probably ineffective interventions {#s7155}
------------------------------------------------------

Panel 2 reports the list of interventions which were low or very low on GRADE quality and thus were categorized as interventions with insufficient evidence. Some of those interventions reported their impact on stillbirths, perinatal or neonatal mortality and those includes family planning ([@bb0340]), periconceptional folic acid supplementation ([@bb0345], [@bb0350]), folic acid supplementation during pregnancy ([@bb0355], [@bb0360]), smoking cessation during pregnancy ([@bb0365], [@bb0370]), calcium supplementation during pregnancy ([@bb0375], [@bb0380]), magnesium sulphate compared to phenytoin for prevention and management of pre-eclampsia ([@bb0385], [@bb0390], [@bb0395], [@bb0400]), external cephalic version ([@bb0405], [@bb0410], [@bb0415], [@bb0420]), induction of labor for PROM ([@bb0425]), antibiotics for PROM ([@bb0430], [@bb0435]), active management for third stage of labor ([@bb0440],), thermal care ([@bb0445]), neonatal resuscitation with bad and mask ([@bb0450]), presumptive antibiotic therapy for newborn ([@bb0455],), Comprehensive care of children infected or exposed to HIV infection ([@bb0460]), Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months ([@bb0465]), and case management of diarrhea ([@bb0470]).

5. Discussion {#s0170}
=============

There have been many great successes in reducing neonatal mortality as part of the MDGs, however, the current rates are still too high since each year 2.9 million newborns do not live to their first month of life ([@bb0295]). In order to accelerate the progress towards reaching the targets set for 2015, this overview aimed to identify key interventions for neonatal and later survival. Review of all the recent Cochrane and other reviews on pre-pregnancy, pregnancy, neonatal and child health interventions which have reported perinatal or neonatal and child mortality identified six highly effective and 11 promising interventions which are likely to improve health and survival among babies. During the past decade, notable advances have been made in reviewing the evidence base for newborn interventions ([@bb0305], [@bb0300]), especially in the context of essential interventions, packages of care and their interconnections ([@bb0310]).

The key effective interventions for improving the survival identified in this overview include antenatal corticosteroids for preventing neonatal RDS in preterm infants; early initiation of breastfeeding; hygienic cord care; KMC for preterm infants; provision and promotion of use of ITNs for children; and vitamin A supplementation for infants from six months of age. Among these, four are particularly effective for neonates, while two had clear implications for improving the survival among infants and children. Most of the interventions identified are very effective for premature infants, as deaths from preterm births complications are the leading cause for neonatal deaths ([@bb0305]). Every year, an estimated 15 million babies are born preterm. Of these over one million die. The common cause of neonatal mortality is RDS which is related to prematurity. The incidence of mortality due to prematurity is highest in LMIC ([@bb0315]) where even moderately preterm babies strive for survival. Preventing deaths from preterm births, is therefore of the utmost importance. Administration of antenatal corticosteroids to women at risk of preterm birth can prevent deaths among babies related to RDS. This overview further suggests that the risk of deaths among those who are born too soon can be halved (50%) by encouraging KMC which not only ensures skin-to-skin contact, but promotes breastfeeding and early recognition of danger signs and illnesses in newborns. Similarly, the benefits of breastfeeding have been well documented; with studies suggesting much greater benefits of early vs. late feeding ([@bb0075]). Early initiation of breastfeeding can reduce neonatal deaths by 44%. At the same time hygienic cord care can further reduces mortality by 23%. For children under the age of five years, infections accounts for a large number of deaths. Prevention of malaria particularly in malaria endemic countries can ensure 18% reduction in mortality. Provision of vitamin A for children above 6 months of age, which decreases the susceptibility towards infection, can also improve survival and health.

Despite the clear evidence of these interventions, coverage is still low and therefore their impact to reduce mortality among newborns and children is very poor. The recent Lancet every newborn series ([@bb0305], [@bb0300]) has clearly highlighted that approximately three-quarters of deaths under five years can be averted if countries implement interventions at a coverage of 70--90% by 2025 ([@bb0305]). Considering the example of TT immunization, it is quite evident that 60% increase in coverage in last 25 years has led to 90% reduction in tetanus mortality in babies ([@bb0150]). However, the coverage for insecticide treated bed nets in 2011 is still low 35.3% (5.2%--75.5%) and countries should prioritize mechanisms to increase coverage ([@bb0320]). Moreover, effective interventions such as hygienic cord care, which includes chlorhexidine cord cleansing, and adopting antenatal corticosteroids for preventing neonatal respiratory distress syndrome in preterm infants have very low coverage according to surveys with less than a third of women and neonates in need receiving them ([@bb0325]). Therefore, integrating these interventions into existing neonatal and childhood programs whereby mothers may also receive interventions such TT immunization, ITNs and corticosteroids when at risk at the same time may be an effective way to increase coverage.

High coverage of available interventions by 2025 can prevent almost three-quarters of neonatal deaths, and can save around 2 million lives per year ([@bb0300]). Interventions delivered in packages, especially for the care of small and ill neonates have the potential to save 1.9 million newborn infants ([@bb0300]). Estimate suggests that available interventions can reduce neonatal deaths related to prematurity by 58%, intrapartum by 79% and infections by 84% among neonates ([@bb0300]). Therefore, the implementation of the interventions identified in this overview will be of paramount importance for improving neonatal and child survival especially in the countries with the highest burden of mortality. It is vital to understand that these interventions are central for LMIC where neonatal and child health indicators are still not up to a high standards and many lives are either lost or their quality compromised due to a dearth of simple and effective actions ([@bb0330]). These interventions need to be deployed to all and promoted from the very outset, including the preconception period, which is vital to ensuring that women of child bearing age understand the importance of these interventions for their babies\' health and survival.

A step forward to seeing improvements in annual reductions in neonatal mortality rates would be to pay more attention to the target group for the interventions; funding and resources may need to be reallocated to include stillbirth prevention which has received very little attention so far ([@bb0335]). High fertility rates may also be adding to the problem. Care and resources in LMICs may be inadequate to cover already existing newborns; and increasing numbers of neonates will lead to strains on existing health care systems. Improved access to family planning, contraceptive methods, awareness and education will decrease the disparity and help efforts to achieve decreased neonatal mortality rates ([@bb0300]).

Community-based delivery strategies to increase access to needed care must be foremost to bringing about a positive change in the LMICs because appropriate education and awareness needs to precede interventions. Empowerment of women, removing barriers to accessibility to health care services, increased education and awareness in communities, and shifting the focus to evidence based interventions may help in adopting healthy practices among mothers and improve child survival rates ([@bb0300]). Appropriate, culturally sensitive education and awareness provided to the communities, followed by timely implementation of discussed interventions which can be integrated with existing healthcare practices, will definitely bring the required improvement in child health and survival.

Several limitations do however need to be recognised. First, it is important to consider that many of the interventions assessed in this review demonstrated important reductions in morbidity but may have been underpowered to show differences in neonatal and later survival. Second, it is also important to be aware that some clearly effective interventions, such TT immunization during pregnancy for reducing tetanus related mortality in neonates do not rate highly on GRADE, due to the study designs required to address this issue. Third, it is not possible to account for all the biases involved in the individual primary studies during the conduct of an overview of systematic reviews, where only systematic reviews and not individual primary studies are included. In addition, the high level synthesis of an overview may not always capture important contextual factors, such as educational attainment, socio-economic status, and access to care.

6. Conclusion {#s0175}
=============

The implementation of these interventions will help in achieving the targets set for MDGs 4 and 5. Adoption of effective interventions promises a much needed improvement in neonatal and child outcomes around the world, especially if selected depending on the clinical indications and keeping in mind the need for cost-effectiveness in view of the limited resources in LMICs.

Research in Context {#s0180}
===================

The synthesis of findings from 148 reviews on interventions for mothers and babies showed that steroids for pregnant mothers at risk of delivering babies early, breastfeeding, cord care, kangaroo care for babies born early, treated bednets for children, and vitamin A for babies from six months of age, are effective interventions for improving survival among babies and children. Antenatal care, tetanus injection during pregnancy, drugs to prevent malaria during pregnancy, inducing labour during prolonged pregnancy, use of surfactant and resuscitation to improve breathing among babies, management of infections among babies and children, and home visits during pregnancy and postnatal period, are the promising interventions for their survival.

Author\'s Contribution {#s0185}
======================

ZSL conceptualised the review in consultation with PM, CC, and ZAB and wrote the first draft of the paper with substantial inputs from PM. ZSL, PM contributed to the scientific literature search, screening, collection, and analysis of data for all the included interventions with close inputs from CC and ZAB. All authors saw successive drafts of the paper and provided input. ZSL, PM, CC and ZAB finalized the paper and ZSL is the overall guarantor.

Conflict of Interest {#s0190}
====================

None.

###### 

List of interventions reviewed.

  --------------------------------------------------------------------------------------------------------------------
  Pre pregnancy interventions
   Family planning
   Prevention and management of sexually transmitted infections including HIV
   Folic acid fortification and/or supplementation
  Pregnancy interventions
   Antenatal care
   Iron and folic acid supplementation during pregnancy
   Tetanus immunization in pregnancy
   Prophylactic antimalarial and insecticide treated bednets for preventing malaria in pregnancy
   Interventions for smoking cessation during pregnancy
   Screening and treatment of syphilis
   Prevention and management of HIV and prevention of mother to child transmission in pregnancy
   Calcium supplementation in pregnancy
   Low-dose aspirin for the prevention of pre-eclampsia
   Use of antihypertensive drugs for treating severe hypertension in pregnancy
   Prevention and treatment of eclampsia
   Reduce mal presentation at term using external cephalic version (\> 36 weeks)
   Induction of labour for management of premature rupture of membranes at term.
   Antibiotics for management of preterm rupture of membranes
  Childbirth interventions
   Corticosteroids for preventing neonatal respiratory distress syndrome
   Management of unintended pregnancy
   Social support during childbirth
   Prophylactic antibiotic for caesarean-section
   Prevention of postpartum haemorrhage: prophylactic uterotonic to prevent postpartum haemorrhage
   Active management of third stage of labour to prevent postpartum haemorrhage
   Induction of labour for prolonged pregnancy
   C-section for absolute maternal indication (e.g. obstructed labour and central placenta previa)
   Management of post-partum haemorrhage e.g. uterine massage
   Uterotonics
  Postpartum interventions
   Advice and provision of family planning
   Prevent, measure and treat maternal anaemia
   Detection and management of postpartum sepsis
   Screening and initiation or continuation of ARV therapy for HIV
  Neonatal interventions
   Promotion and provision of thermal care for all newborns to prevent hypothermia
   Promotion and support for early initiation and exclusive breastfeeding (within the first hour)
   Promotion and provision of hygienic cord and skin care
   Neonatal resuscitation with bag and mask for babies who do not breath at birth
   Newborn immunization
   Presumptive antibiotic therapy for the newborns at risk of bacterial infection
   Case management of neonatal sepsis, meningitis and pneumonia
   Kangaroo mother care for low birth babies
   Extra support for feeding the small and preterm baby
   Prophylactic and therapeutic use of surfactant to prevent respiratory distress syndrome in pre-term babies
   Continuous positive airway pressure (CPAP) to manage pre-term babies with respiratory distress syndrome
   Management of newborns with jaundice
  Infant and child health interventions
   Promotion and support for exclusive breastfeeding for 6 months
   Continued breastfeeding up to 2 years and beyond
   Appropriate complementary feeding starting at 6 months
   Provision and promotion of use of insecticide treated bed nets for children
   Case management of childhood malaria
   Comprehensive care of children infected or exposed to HIV infection
   Promote and provide routine immunization plus *H. Influenza*, meningococcal, pneumococcal, and rotavirus vaccines
   Vitamin A supplementation from 6 months of age in Vitamin A deficient populations
   Management of severe acute malnutrition
   Case management of childhood pneumonia
   Vitamin A as part of treatment for measles-associated pneumonia for children above 6 months
   Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months
   Case management of diarrhoea: Acute watery diarrhoea
   Dysentery
  Cross cutting intervention
   Home visits across the continuum of care women\'s groups
  --------------------------------------------------------------------------------------------------------------------

###### 

GRADE interventions according to outcomes.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  What works                                                                    What might work                                                                               Insufficient evidence
  ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  *Mortality (neonatal or infant or child)*                                                                                                                                   

  Corticosteroid for prevention of neonatal respiratory distress syndrome       Tetanus immunization in pregnancy (tetanus toxoid vs. placebo)                                Family planning

  Early initiation of breastfeeding                                             Prophylactic antimalarial during pregnancy                                                    Periconceptional folic acid supplementation

  Hygienic cord care                                                            Induction of labour for prolonged pregnancy                                                   Folic acid supplementation during pregnancy[⁎](#tf0005){ref-type="table-fn"}

  Kangaroo mother care for low birth weight babies                              Case management of neonatal sepsis, meningitis and pneumonia                                  Iron supplementation during pregnancy

  Provision and promotion of use of insecticide treated bed nets for children   Prophylactic and therapeutic use of surfactant                                                Tetanus immunization in pregnancy (TT vs. diphtheria and influenza)

  Vitamin A supplementation from 6 months of age                                Continuous positive airway pressure (CPAP)                                                    Smoking cessation during pregnancy

                                                                                Case management of childhood malaria                                                          Prevention and treatment of eclampsia

                                                                                Case management of childhood pneumonia                                                        Active management for third stage of labour

                                                                                Vitamin A as part of treatment for measles associated pneumonia for children above 6 months   Induction of labour for PROM

                                                                                Home visits across the continuum of care women\'s groups                                      Antibiotic for PROM

                                                                                                                                                                              Thermal care for all newborns

                                                                                                                                                                              Neonatal resuscitation with bag and mask

                                                                                                                                                                              Presumptive antibiotic therapy for newborns

                                                                                                                                                                              Case management of childhood malaria (monthly sulfadoxine pyrimethamine (SP) compared to standard 2-dose SP)

                                                                                                                                                                              Comprehensive care of children infected or exposed to HIV infection

                                                                                                                                                                              Vitamin A as part of treatment for non-measles-associated pneumonia for children above 6 months

                                                                                                                                                                              Case management of diarrhoea

                                                                                                                                                                              

  *Perinatal mortality*                                                                                                                                                       

                                                                                Antenatal care                                                                                Periconceptional folic acid supplementation vs. placebo

                                                                                Prophylactic antimalarial during pregnancy                                                    Smoking cessation during pregnancy

                                                                                Induction of labour for prolonged pregnancy                                                   Calcium supplementation

                                                                                Home visits across the continuum of care women\'s groups                                      Prevention and treatment of eclampsia\
                                                                                                                                                                              (MgSO4 vs. none or other)

                                                                                                                                                                              External cephalic version

                                                                                                                                                                              Induction of labour for PROM

                                                                                                                                                                              Antibiotic for PROM[⁎⁎](#tf0010){ref-type="table-fn"}

                                                                                                                                                                              Corticosteroid for prevention of neonatal RDS (dexamethasone versus betamethasone)

                                                                                                                                                                              

  *Stillbirths*                                                                                                                                                               

                                                                                Provision and promotion of ITNs[⁎⁎⁎](#tf0015){ref-type="table-fn"}                            Periconceptional folic acid supplementation vs. no treatment/placebo

                                                                                Prophylactic antimalarial during pregnancy                                                    Folic acid supplementation during pregnancy[⁎](#tf0005){ref-type="table-fn"}

                                                                                Induction of labour for prolonged pregnancy                                                   Smoking cessation during pregnancy

                                                                                Home visits across the continuum of care women\'s groups                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Interventions in bold indicate that the outcomes estimates were statistically significant.

Stillbirths + neonatal mortality.

Perinatal mortality or death before discharge.

Foetal loss (miscarriage and stillbirths).

###### 

Grading analysis of mortality outcomes from included reviews.
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